Han Kiwon, Commissioner, Invest Korea
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Invest Korea (IK), Korea’s national investment promotion agency, was established within the Korea Trade-Investment Promotion Agency (KOTRA) with the sole purpose of supporting the entry and successful establishment of foreign business into Korea. With assistance extending to comprehensive post-establishment services, IK enables foreign corporations to maximize the benefits of the Korean investment environment to ensure their rapid settlement in Korea. The agency is committed to providing unmatched, comprehensive one-stop service that allows foreign investors to join many of the world’s most successful corporations who have selected Korea as an investment destination and been rewarded by high returns on the investment.
Contact Details
13, Heolleung-ro Seocho-gu,
Seoul
Republic of Korea (137-749)
Tel. 82-1600-7119
E-mail ikonline@kotra.or.kr
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He also explains recent partnerships in China.…
The latest healthcare and pharma news from South Korea, including SK Bioscience’s COVID-19 vaccine, Daewoong’s partnership with AstraZeneca Korea and UCI Therapeutics, Vivozon production halt and GC’s acquistion of US-based…
Chair & Founder, Regenerative Medicine Acceleration Foundation (RMAF), So Ra Park MD, PhD*, comments on the regenerative medicine ecosystem in Korea, the country’s new legislative approach to the field, and…
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the…
Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s…
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand…
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D. Cho also compares the challenges of the Chinese market with the potential…
See our Cookie Privacy Policy Here
